News and Announcements
30 Global Exchanges on One Cost-Effective Global Research & Investment Solution
- Published November 11, 2022 5:14AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Designed by fund managers and tested by investors. HALO is a cost-effective way to help investors invest directly in both local and international shares.
Institutional-grade capabilities
HALO was originally created by legendary Australian hedge fund manager, Nicolas Bryon, to power his own international trading.
HALO gives investors instant access to over 30,000 global equities and ETFs across 30 different exchanges, including the ASX, NASDAQ, New York Stock Exchange, London Stock Exchange, Nikkei, and more.
HALO features institutional-grade investment and portfolio management tools to help investors navigate markets confidently – from premium research to our powerful ProTools Scanner, and market-leading charting interface.
HALO makes it easy to invest cost-effectively in the world’s biggest and fastest growing companies in a way that supports investors goals.
Thematic share portfolios
HALO not only makes it easy to invest in individual securities, it also features 28 thematic share portfolios investors can use to give them access to a selected basket of stocks in a single trade.
Known as Vues, each 10-stock portfolio is designed to capture a key global trend, issue, or investment style.
Try HALO for yourself:
Special Offer: $300 brokerage + 3 Investing Reports for 3 months.
333 OFFER includes:
- $300 complimentary brokerage to use within 3 months.
- 3 months complimentary subscription to HALO’s Americas Investing Report, Asia Investing Report and EMEA Investing Report.
- Each report contains company insights for each region, carefully researched and selected by HALO’s Global Equity Research team.
- Investors receive 2 reports for each region per month.
To redeem fill out the form below and use ‘WI333’ as the promo code:
Connect with the company and learn more about HALO by accessing their deal room here.
Company Updates
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain
In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]
Backed By Leading Investment Groups and Family Offices
